Mizuho Securities Downgrades Spark Therapeutics (ONCE) to Neutral Following Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BTIG Expects Sarepta Therapeutics (SRPT) To Pop On Competitor Acquisition
February 25, 2019 8:48 AM ESTBTIG analyst, Timothy Chiang, reiterated his Buy rating on shares of Sarepta Therapeutics (NASDAQ: SRPT) and believes shares will get a lift on news of Roche (OTC: RHHBY) acquiring Spark Therapeutics (NASDAQ:... More
Spark Therapeutics (ONCE) to be Acquired by Roche for $114.50/Share
February 25, 2019 6:10 AM ESTSpark Therapeutics (NASDAQ: ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction. This corresponds to a total equity value of approximately $4.8 billion on a fully diluted basis, inclusive of approximately $500 million of projected net cash expected at close. The per share price represents a premium of 122 percent to Sparks closing price on Feb. 22, 2019. The merger agreement has been... More
